

GOVERNMENT OF INDIA  
MINISTRY OF CHEMICALS AND FERTILIZERS  
DEPARTMENT OF PHARMACEUTICALS

**LOK SABHA**

**UNSTARRED QUESTION No. 813**

**TO BE ANSWERED ON THE 1<sup>st</sup> March, 2016**

**Manufacturing of Saxagliptin Drug**

813. DR. GOKARAJU GANGA RAJU:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether it is a fact that nearly 80% diabetics in the country belong to low and middle-income groups and that over 80% of diabetes deaths in the world occur in low and middle-income countries like India;
- (b) if so, the details thereof;
- (c) whether it is true that even after eight years of grant of patent, the Saxagliptin drug is still not manufactured in the country and is being imported and that too in insufficient quantities and at exorbitant price, which does not cater to the requirement of the country;
- (d) if so, the measures taken by the Government to make available this drug in the country;
- (e) whether any domestic drug manufacturer has approached the Government to manufacture the drug in a bid to substantially bring down its cost; and
- (f) if so, the details thereof?

**ANSWER**

**MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANSRAJ GANGARAM AHIR)**

(a) & (b): The information is not available with the Department. However, it has been reported that the number of diabetic patients in the country are rising and India is likely to become a hub of diabetic patients in the near future.

(c) & (d): The Sexagliptin drug is protected by Patent number 206543 titled "A CYCLOPROPYL-FUSED PYRROLIDINE-BASED COMPOUND" granted on 30<sup>th</sup> April 2007 to Bristol Myers Squibb Company (BMS).

(e) & (f): M/s Lee Pharma filed an application for grant of CL under Section 84(1) of The Patents Act, 1970. This application was rejected by the Controller of Patents, Patent Office, Mumbai.

Xxxxx